Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
8,908
archived clinical trials in
Renal Impairment / Chronic Kidney Disease

Effects of Exercise and Improved Nitric Oxide Bioavailability on Arteriovenous Fistula Maturation
Effects of Exercise and Improved Nitric Oxide Bioavailability on Arteriovenous Fistula Maturation
Status: Enrolling
Updated:  6/16/2017
Duke University Health System
mi
from
Durham, NC
Effects of Exercise and Improved Nitric Oxide Bioavailability on Arteriovenous Fistula Maturation
Effects of Exercise and Improved Nitric Oxide Bioavailability on Arteriovenous Fistula Maturation
Status: Enrolling
Updated: 6/16/2017
Duke University Health System
mi
from
Durham, NC
Click here to add this to my saved trials
Study of Belatacept in Subjects Who Are Undergoing a Renal Transplant
Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression Trial - Extended Criteria Donors (BENEFIT-EXT)
Status: Enrolling
Updated:  6/28/2017
University of Alabama at Birmingham
mi
from
Birmingham, AL
Study of Belatacept in Subjects Who Are Undergoing a Renal Transplant
Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression Trial - Extended Criteria Donors (BENEFIT-EXT)
Status: Enrolling
Updated: 6/28/2017
University of Alabama at Birmingham
mi
from
Birmingham, AL
Click here to add this to my saved trials
Study of Belatacept in Subjects Who Are Undergoing a Renal Transplant
Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression Trial - Extended Criteria Donors (BENEFIT-EXT)
Status: Enrolling
Updated:  6/28/2017
Ucla Kidney & Kidney-Pancreas Transplant Research Office
mi
from
Los Angeles, CA
Study of Belatacept in Subjects Who Are Undergoing a Renal Transplant
Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression Trial - Extended Criteria Donors (BENEFIT-EXT)
Status: Enrolling
Updated: 6/28/2017
Ucla Kidney & Kidney-Pancreas Transplant Research Office
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Study of Belatacept in Subjects Who Are Undergoing a Renal Transplant
Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression Trial - Extended Criteria Donors (BENEFIT-EXT)
Status: Enrolling
Updated:  6/28/2017
National Institute Of Transplantation
mi
from
Los Angeles, CA
Study of Belatacept in Subjects Who Are Undergoing a Renal Transplant
Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression Trial - Extended Criteria Donors (BENEFIT-EXT)
Status: Enrolling
Updated: 6/28/2017
National Institute Of Transplantation
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Study of Belatacept in Subjects Who Are Undergoing a Renal Transplant
Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression Trial - Extended Criteria Donors (BENEFIT-EXT)
Status: Enrolling
Updated:  6/28/2017
Sharp Memorial Hospital
mi
from
San Diego, CA
Study of Belatacept in Subjects Who Are Undergoing a Renal Transplant
Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression Trial - Extended Criteria Donors (BENEFIT-EXT)
Status: Enrolling
Updated: 6/28/2017
Sharp Memorial Hospital
mi
from
San Diego, CA
Click here to add this to my saved trials
Study of Belatacept in Subjects Who Are Undergoing a Renal Transplant
Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression Trial - Extended Criteria Donors (BENEFIT-EXT)
Status: Enrolling
Updated:  6/28/2017
University of California, San Francisco Medical Center
mi
from
San Francisco, CA
Study of Belatacept in Subjects Who Are Undergoing a Renal Transplant
Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression Trial - Extended Criteria Donors (BENEFIT-EXT)
Status: Enrolling
Updated: 6/28/2017
University of California, San Francisco Medical Center
mi
from
San Francisco, CA
Click here to add this to my saved trials
Study of Belatacept in Subjects Who Are Undergoing a Renal Transplant
Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression Trial - Extended Criteria Donors (BENEFIT-EXT)
Status: Enrolling
Updated:  6/28/2017
University of Colorado Health Sciences Ctr.
mi
from
Aurora, CO
Study of Belatacept in Subjects Who Are Undergoing a Renal Transplant
Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression Trial - Extended Criteria Donors (BENEFIT-EXT)
Status: Enrolling
Updated: 6/28/2017
University of Colorado Health Sciences Ctr.
mi
from
Aurora, CO
Click here to add this to my saved trials
Study of Belatacept in Subjects Who Are Undergoing a Renal Transplant
Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression Trial - Extended Criteria Donors (BENEFIT-EXT)
Status: Enrolling
Updated:  6/28/2017
Yale University School of Medicine
mi
from
New Haven, CT
Study of Belatacept in Subjects Who Are Undergoing a Renal Transplant
Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression Trial - Extended Criteria Donors (BENEFIT-EXT)
Status: Enrolling
Updated: 6/28/2017
Yale University School of Medicine
mi
from
New Haven, CT
Click here to add this to my saved trials
Study of Belatacept in Subjects Who Are Undergoing a Renal Transplant
Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression Trial - Extended Criteria Donors (BENEFIT-EXT)
Status: Enrolling
Updated:  6/28/2017
Lifelink Healthcare Institute
mi
from
Tampa, FL
Study of Belatacept in Subjects Who Are Undergoing a Renal Transplant
Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression Trial - Extended Criteria Donors (BENEFIT-EXT)
Status: Enrolling
Updated: 6/28/2017
Lifelink Healthcare Institute
mi
from
Tampa, FL
Click here to add this to my saved trials
Study of Belatacept in Subjects Who Are Undergoing a Renal Transplant
Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression Trial - Extended Criteria Donors (BENEFIT-EXT)
Status: Enrolling
Updated:  6/28/2017
Piedmont Transplant Institute
mi
from
Atlanta, GA
Study of Belatacept in Subjects Who Are Undergoing a Renal Transplant
Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression Trial - Extended Criteria Donors (BENEFIT-EXT)
Status: Enrolling
Updated: 6/28/2017
Piedmont Transplant Institute
mi
from
Atlanta, GA
Click here to add this to my saved trials
Study of Belatacept in Subjects Who Are Undergoing a Renal Transplant
Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression Trial - Extended Criteria Donors (BENEFIT-EXT)
Status: Enrolling
Updated:  6/28/2017
Emory University Hospital
mi
from
Atlanta, GA
Study of Belatacept in Subjects Who Are Undergoing a Renal Transplant
Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression Trial - Extended Criteria Donors (BENEFIT-EXT)
Status: Enrolling
Updated: 6/28/2017
Emory University Hospital
mi
from
Atlanta, GA
Click here to add this to my saved trials
Study of Belatacept in Subjects Who Are Undergoing a Renal Transplant
Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression Trial - Extended Criteria Donors (BENEFIT-EXT)
Status: Enrolling
Updated:  6/28/2017
Northwestern University Feinberg School of Medicine
mi
from
Chicago, IL
Study of Belatacept in Subjects Who Are Undergoing a Renal Transplant
Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression Trial - Extended Criteria Donors (BENEFIT-EXT)
Status: Enrolling
Updated: 6/28/2017
Northwestern University Feinberg School of Medicine
mi
from
Chicago, IL
Click here to add this to my saved trials
Study of Belatacept in Subjects Who Are Undergoing a Renal Transplant
Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression Trial - Extended Criteria Donors (BENEFIT-EXT)
Status: Enrolling
Updated:  6/28/2017
The University of Chicago Hospitals
mi
from
Chicago, IL
Study of Belatacept in Subjects Who Are Undergoing a Renal Transplant
Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression Trial - Extended Criteria Donors (BENEFIT-EXT)
Status: Enrolling
Updated: 6/28/2017
The University of Chicago Hospitals
mi
from
Chicago, IL
Click here to add this to my saved trials
Study of Belatacept in Subjects Who Are Undergoing a Renal Transplant
Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression Trial - Extended Criteria Donors (BENEFIT-EXT)
Status: Enrolling
Updated:  6/28/2017
Acadiana Renal Physicians
mi
from
New Iberia, LA
Study of Belatacept in Subjects Who Are Undergoing a Renal Transplant
Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression Trial - Extended Criteria Donors (BENEFIT-EXT)
Status: Enrolling
Updated: 6/28/2017
Acadiana Renal Physicians
mi
from
New Iberia, LA
Click here to add this to my saved trials
Study of Belatacept in Subjects Who Are Undergoing a Renal Transplant
Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression Trial - Extended Criteria Donors (BENEFIT-EXT)
Status: Enrolling
Updated:  6/28/2017
Tulane Abdominal Transplant Institute
mi
from
New Orleans, LA
Study of Belatacept in Subjects Who Are Undergoing a Renal Transplant
Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression Trial - Extended Criteria Donors (BENEFIT-EXT)
Status: Enrolling
Updated: 6/28/2017
Tulane Abdominal Transplant Institute
mi
from
New Orleans, LA
Click here to add this to my saved trials
Study of Belatacept in Subjects Who Are Undergoing a Renal Transplant
Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression Trial - Extended Criteria Donors (BENEFIT-EXT)
Status: Enrolling
Updated:  6/28/2017
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Study of Belatacept in Subjects Who Are Undergoing a Renal Transplant
Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression Trial - Extended Criteria Donors (BENEFIT-EXT)
Status: Enrolling
Updated: 6/28/2017
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
Study of Belatacept in Subjects Who Are Undergoing a Renal Transplant
Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression Trial - Extended Criteria Donors (BENEFIT-EXT)
Status: Enrolling
Updated:  6/28/2017
Western New England Renal & Transplant Associates, PC
mi
from
Springfield, MA
Study of Belatacept in Subjects Who Are Undergoing a Renal Transplant
Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression Trial - Extended Criteria Donors (BENEFIT-EXT)
Status: Enrolling
Updated: 6/28/2017
Western New England Renal & Transplant Associates, PC
mi
from
Springfield, MA
Click here to add this to my saved trials
Study of Belatacept in Subjects Who Are Undergoing a Renal Transplant
Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression Trial - Extended Criteria Donors (BENEFIT-EXT)
Status: Enrolling
Updated:  6/28/2017
Univ of Minnesota
mi
from
Minneapolis, MN
Study of Belatacept in Subjects Who Are Undergoing a Renal Transplant
Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression Trial - Extended Criteria Donors (BENEFIT-EXT)
Status: Enrolling
Updated: 6/28/2017
Univ of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Study of Belatacept in Subjects Who Are Undergoing a Renal Transplant
Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression Trial - Extended Criteria Donors (BENEFIT-EXT)
Status: Enrolling
Updated:  6/28/2017
Washington University School of Medicine
mi
from
Saint Louis, MO
Study of Belatacept in Subjects Who Are Undergoing a Renal Transplant
Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression Trial - Extended Criteria Donors (BENEFIT-EXT)
Status: Enrolling
Updated: 6/28/2017
Washington University School of Medicine
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Study of Belatacept in Subjects Who Are Undergoing a Renal Transplant
Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression Trial - Extended Criteria Donors (BENEFIT-EXT)
Status: Enrolling
Updated:  6/28/2017
Mount Sinai School of Medicine
mi
from
New York, NY
Study of Belatacept in Subjects Who Are Undergoing a Renal Transplant
Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression Trial - Extended Criteria Donors (BENEFIT-EXT)
Status: Enrolling
Updated: 6/28/2017
Mount Sinai School of Medicine
mi
from
New York, NY
Click here to add this to my saved trials
Study of Belatacept in Subjects Who Are Undergoing a Renal Transplant
Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression Trial - Extended Criteria Donors (BENEFIT-EXT)
Status: Enrolling
Updated:  6/28/2017
Columbia University College of Physicians and Surgeons
mi
from
New York, NY
Study of Belatacept in Subjects Who Are Undergoing a Renal Transplant
Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression Trial - Extended Criteria Donors (BENEFIT-EXT)
Status: Enrolling
Updated: 6/28/2017
Columbia University College of Physicians and Surgeons
mi
from
New York, NY
Click here to add this to my saved trials
Study of Belatacept in Subjects Who Are Undergoing a Renal Transplant
Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression Trial - Extended Criteria Donors (BENEFIT-EXT)
Status: Enrolling
Updated:  6/28/2017
University of North Carolina at Chapel Hill
mi
from
Chapel Hill, NC
Study of Belatacept in Subjects Who Are Undergoing a Renal Transplant
Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression Trial - Extended Criteria Donors (BENEFIT-EXT)
Status: Enrolling
Updated: 6/28/2017
University of North Carolina at Chapel Hill
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Study of Belatacept in Subjects Who Are Undergoing a Renal Transplant
Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression Trial - Extended Criteria Donors (BENEFIT-EXT)
Status: Enrolling
Updated:  6/28/2017
Carolinas Medical Center
mi
from
Charlotte, NC
Study of Belatacept in Subjects Who Are Undergoing a Renal Transplant
Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression Trial - Extended Criteria Donors (BENEFIT-EXT)
Status: Enrolling
Updated: 6/28/2017
Carolinas Medical Center
mi
from
Charlotte, NC
Click here to add this to my saved trials
Study of Belatacept in Subjects Who Are Undergoing a Renal Transplant
Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression Trial - Extended Criteria Donors (BENEFIT-EXT)
Status: Enrolling
Updated:  6/28/2017
Drexel University College Of Medicine, Department Of Surgery
mi
from
Philadelphia, PA
Study of Belatacept in Subjects Who Are Undergoing a Renal Transplant
Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression Trial - Extended Criteria Donors (BENEFIT-EXT)
Status: Enrolling
Updated: 6/28/2017
Drexel University College Of Medicine, Department Of Surgery
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Study of Belatacept in Subjects Who Are Undergoing a Renal Transplant
Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression Trial - Extended Criteria Donors (BENEFIT-EXT)
Status: Enrolling
Updated:  6/28/2017
Univ of Pennsylvania
mi
from
Philadelphia, PA
Study of Belatacept in Subjects Who Are Undergoing a Renal Transplant
Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression Trial - Extended Criteria Donors (BENEFIT-EXT)
Status: Enrolling
Updated: 6/28/2017
Univ of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Study of Belatacept in Subjects Who Are Undergoing a Renal Transplant
Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression Trial - Extended Criteria Donors (BENEFIT-EXT)
Status: Enrolling
Updated:  6/28/2017
Baylor University Medical Center
mi
from
Dallas, TX
Study of Belatacept in Subjects Who Are Undergoing a Renal Transplant
Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression Trial - Extended Criteria Donors (BENEFIT-EXT)
Status: Enrolling
Updated: 6/28/2017
Baylor University Medical Center
mi
from
Dallas, TX
Click here to add this to my saved trials
Study of Belatacept in Subjects Who Are Undergoing a Renal Transplant
Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression Trial - Extended Criteria Donors (BENEFIT-EXT)
Status: Enrolling
Updated:  6/28/2017
University of Wisconsin
mi
from
Madison, WI
Study of Belatacept in Subjects Who Are Undergoing a Renal Transplant
Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression Trial - Extended Criteria Donors (BENEFIT-EXT)
Status: Enrolling
Updated: 6/28/2017
University of Wisconsin
mi
from
Madison, WI
Click here to add this to my saved trials
Study of Belatacept in Subjects Who Are Undergoing a Renal Transplant
Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression Trial - Extended Criteria Donors (BENEFIT-EXT)
Status: Enrolling
Updated:  6/28/2017
Froedtert Memorial Hospital
mi
from
Milwaukee, WI
Study of Belatacept in Subjects Who Are Undergoing a Renal Transplant
Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression Trial - Extended Criteria Donors (BENEFIT-EXT)
Status: Enrolling
Updated: 6/28/2017
Froedtert Memorial Hospital
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Study of Belatacept in Subjects Who Are Undergoing a Renal Transplant
Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression Trial - Extended Criteria Donors (BENEFIT-EXT)
Status: Enrolling
Updated:  6/28/2017
Local Institution
mi
from
Capital Federal,
Study of Belatacept in Subjects Who Are Undergoing a Renal Transplant
Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression Trial - Extended Criteria Donors (BENEFIT-EXT)
Status: Enrolling
Updated: 6/28/2017
Local Institution
mi
from
Capital Federal,
Click here to add this to my saved trials
Study of Belatacept in Subjects Who Are Undergoing a Renal Transplant
Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression Trial - Extended Criteria Donors (BENEFIT-EXT)
Status: Enrolling
Updated:  6/28/2017
Henry Ford Hospital, Transplant Institute
mi
from
Detroit, MI
Study of Belatacept in Subjects Who Are Undergoing a Renal Transplant
Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression Trial - Extended Criteria Donors (BENEFIT-EXT)
Status: Enrolling
Updated: 6/28/2017
Henry Ford Hospital, Transplant Institute
mi
from
Detroit, MI
Click here to add this to my saved trials
To Assess the Long-term Safety of AMG 416 in the Treatment of SHPT in Subjects With CKD on Hemodialysis
A Multicenter Single-arm Extension Study to Describe the Long-term Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis
Status: Enrolling
Updated:  7/11/2017
Clinical Research Facility
mi
from
Birmingham, AL
To Assess the Long-term Safety of AMG 416 in the Treatment of SHPT in Subjects With CKD on Hemodialysis
A Multicenter Single-arm Extension Study to Describe the Long-term Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis
Status: Enrolling
Updated: 7/11/2017
Clinical Research Facility
mi
from
Birmingham, AL
Click here to add this to my saved trials
To Assess the Long-term Safety of AMG 416 in the Treatment of SHPT in Subjects With CKD on Hemodialysis
A Multicenter Single-arm Extension Study to Describe the Long-term Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis
Status: Enrolling
Updated:  7/11/2017
Clinical Research Facility
mi
from
Alhambra, CA
To Assess the Long-term Safety of AMG 416 in the Treatment of SHPT in Subjects With CKD on Hemodialysis
A Multicenter Single-arm Extension Study to Describe the Long-term Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis
Status: Enrolling
Updated: 7/11/2017
Clinical Research Facility
mi
from
Alhambra, CA
Click here to add this to my saved trials
To Assess the Long-term Safety of AMG 416 in the Treatment of SHPT in Subjects With CKD on Hemodialysis
A Multicenter Single-arm Extension Study to Describe the Long-term Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis
Status: Enrolling
Updated:  7/11/2017
Clinical Research Facility
mi
from
Azusa, CA
To Assess the Long-term Safety of AMG 416 in the Treatment of SHPT in Subjects With CKD on Hemodialysis
A Multicenter Single-arm Extension Study to Describe the Long-term Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis
Status: Enrolling
Updated: 7/11/2017
Clinical Research Facility
mi
from
Azusa, CA
Click here to add this to my saved trials
To Assess the Long-term Safety of AMG 416 in the Treatment of SHPT in Subjects With CKD on Hemodialysis
A Multicenter Single-arm Extension Study to Describe the Long-term Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis
Status: Enrolling
Updated:  7/11/2017
Clinical Research Facility
mi
from
Bakersfield, CA
To Assess the Long-term Safety of AMG 416 in the Treatment of SHPT in Subjects With CKD on Hemodialysis
A Multicenter Single-arm Extension Study to Describe the Long-term Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis
Status: Enrolling
Updated: 7/11/2017
Clinical Research Facility
mi
from
Bakersfield, CA
Click here to add this to my saved trials
To Assess the Long-term Safety of AMG 416 in the Treatment of SHPT in Subjects With CKD on Hemodialysis
A Multicenter Single-arm Extension Study to Describe the Long-term Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis
Status: Enrolling
Updated:  7/11/2017
Clinical Research Facility
mi
from
Cudahy, CA
To Assess the Long-term Safety of AMG 416 in the Treatment of SHPT in Subjects With CKD on Hemodialysis
A Multicenter Single-arm Extension Study to Describe the Long-term Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis
Status: Enrolling
Updated: 7/11/2017
Clinical Research Facility
mi
from
Cudahy, CA
Click here to add this to my saved trials
To Assess the Long-term Safety of AMG 416 in the Treatment of SHPT in Subjects With CKD on Hemodialysis
A Multicenter Single-arm Extension Study to Describe the Long-term Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis
Status: Enrolling
Updated:  7/11/2017
Clinical Research Facility
mi
from
Granada Hills, CA
To Assess the Long-term Safety of AMG 416 in the Treatment of SHPT in Subjects With CKD on Hemodialysis
A Multicenter Single-arm Extension Study to Describe the Long-term Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis
Status: Enrolling
Updated: 7/11/2017
Clinical Research Facility
mi
from
Granada Hills, CA
Click here to add this to my saved trials
To Assess the Long-term Safety of AMG 416 in the Treatment of SHPT in Subjects With CKD on Hemodialysis
A Multicenter Single-arm Extension Study to Describe the Long-term Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis
Status: Enrolling
Updated:  7/11/2017
Clinical Research Facility
mi
from
Los Angeles, CA
To Assess the Long-term Safety of AMG 416 in the Treatment of SHPT in Subjects With CKD on Hemodialysis
A Multicenter Single-arm Extension Study to Describe the Long-term Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis
Status: Enrolling
Updated: 7/11/2017
Clinical Research Facility
mi
from
Los Angeles, CA
Click here to add this to my saved trials
To Assess the Long-term Safety of AMG 416 in the Treatment of SHPT in Subjects With CKD on Hemodialysis
A Multicenter Single-arm Extension Study to Describe the Long-term Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis
Status: Enrolling
Updated:  7/11/2017
Clinical Research Facility
mi
from
Los Angeles, CA
To Assess the Long-term Safety of AMG 416 in the Treatment of SHPT in Subjects With CKD on Hemodialysis
A Multicenter Single-arm Extension Study to Describe the Long-term Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis
Status: Enrolling
Updated: 7/11/2017
Clinical Research Facility
mi
from
Los Angeles, CA
Click here to add this to my saved trials
To Assess the Long-term Safety of AMG 416 in the Treatment of SHPT in Subjects With CKD on Hemodialysis
A Multicenter Single-arm Extension Study to Describe the Long-term Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis
Status: Enrolling
Updated:  7/11/2017
Clinical Research Facility
mi
from
Northridge, CA
To Assess the Long-term Safety of AMG 416 in the Treatment of SHPT in Subjects With CKD on Hemodialysis
A Multicenter Single-arm Extension Study to Describe the Long-term Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis
Status: Enrolling
Updated: 7/11/2017
Clinical Research Facility
mi
from
Northridge, CA
Click here to add this to my saved trials
To Assess the Long-term Safety of AMG 416 in the Treatment of SHPT in Subjects With CKD on Hemodialysis
A Multicenter Single-arm Extension Study to Describe the Long-term Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis
Status: Enrolling
Updated:  7/11/2017
Clinical Research Facility
mi
from
Riverside, CA
To Assess the Long-term Safety of AMG 416 in the Treatment of SHPT in Subjects With CKD on Hemodialysis
A Multicenter Single-arm Extension Study to Describe the Long-term Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis
Status: Enrolling
Updated: 7/11/2017
Clinical Research Facility
mi
from
Riverside, CA
Click here to add this to my saved trials
To Assess the Long-term Safety of AMG 416 in the Treatment of SHPT in Subjects With CKD on Hemodialysis
A Multicenter Single-arm Extension Study to Describe the Long-term Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis
Status: Enrolling
Updated:  7/11/2017
Clinical Research Facility
mi
from
Simi Valley, CA
To Assess the Long-term Safety of AMG 416 in the Treatment of SHPT in Subjects With CKD on Hemodialysis
A Multicenter Single-arm Extension Study to Describe the Long-term Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis
Status: Enrolling
Updated: 7/11/2017
Clinical Research Facility
mi
from
Simi Valley, CA
Click here to add this to my saved trials
To Assess the Long-term Safety of AMG 416 in the Treatment of SHPT in Subjects With CKD on Hemodialysis
A Multicenter Single-arm Extension Study to Describe the Long-term Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis
Status: Enrolling
Updated:  7/11/2017
Clinical Research Facility
mi
from
Vacaville, CA
To Assess the Long-term Safety of AMG 416 in the Treatment of SHPT in Subjects With CKD on Hemodialysis
A Multicenter Single-arm Extension Study to Describe the Long-term Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis
Status: Enrolling
Updated: 7/11/2017
Clinical Research Facility
mi
from
Vacaville, CA
Click here to add this to my saved trials
To Assess the Long-term Safety of AMG 416 in the Treatment of SHPT in Subjects With CKD on Hemodialysis
A Multicenter Single-arm Extension Study to Describe the Long-term Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis
Status: Enrolling
Updated:  7/11/2017
Clinical Research Facility
mi
from
Whittier, CA
To Assess the Long-term Safety of AMG 416 in the Treatment of SHPT in Subjects With CKD on Hemodialysis
A Multicenter Single-arm Extension Study to Describe the Long-term Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis
Status: Enrolling
Updated: 7/11/2017
Clinical Research Facility
mi
from
Whittier, CA
Click here to add this to my saved trials
To Assess the Long-term Safety of AMG 416 in the Treatment of SHPT in Subjects With CKD on Hemodialysis
A Multicenter Single-arm Extension Study to Describe the Long-term Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis
Status: Enrolling
Updated:  7/11/2017
Clinical Research Facility
mi
from
Aurora, CO
To Assess the Long-term Safety of AMG 416 in the Treatment of SHPT in Subjects With CKD on Hemodialysis
A Multicenter Single-arm Extension Study to Describe the Long-term Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis
Status: Enrolling
Updated: 7/11/2017
Clinical Research Facility
mi
from
Aurora, CO
Click here to add this to my saved trials
To Assess the Long-term Safety of AMG 416 in the Treatment of SHPT in Subjects With CKD on Hemodialysis
A Multicenter Single-arm Extension Study to Describe the Long-term Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis
Status: Enrolling
Updated:  7/11/2017
Clinical Research Facility
mi
from
Westminster, CO
To Assess the Long-term Safety of AMG 416 in the Treatment of SHPT in Subjects With CKD on Hemodialysis
A Multicenter Single-arm Extension Study to Describe the Long-term Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis
Status: Enrolling
Updated: 7/11/2017
Clinical Research Facility
mi
from
Westminster, CO
Click here to add this to my saved trials
To Assess the Long-term Safety of AMG 416 in the Treatment of SHPT in Subjects With CKD on Hemodialysis
A Multicenter Single-arm Extension Study to Describe the Long-term Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis
Status: Enrolling
Updated:  7/11/2017
Clinical Research Facility
mi
from
Stamford, CT
To Assess the Long-term Safety of AMG 416 in the Treatment of SHPT in Subjects With CKD on Hemodialysis
A Multicenter Single-arm Extension Study to Describe the Long-term Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis
Status: Enrolling
Updated: 7/11/2017
Clinical Research Facility
mi
from
Stamford, CT
Click here to add this to my saved trials
To Assess the Long-term Safety of AMG 416 in the Treatment of SHPT in Subjects With CKD on Hemodialysis
A Multicenter Single-arm Extension Study to Describe the Long-term Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis
Status: Enrolling
Updated:  7/11/2017
Clinical Research Facility
mi
from
Miami, FL
To Assess the Long-term Safety of AMG 416 in the Treatment of SHPT in Subjects With CKD on Hemodialysis
A Multicenter Single-arm Extension Study to Describe the Long-term Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis
Status: Enrolling
Updated: 7/11/2017
Clinical Research Facility
mi
from
Miami, FL
Click here to add this to my saved trials
To Assess the Long-term Safety of AMG 416 in the Treatment of SHPT in Subjects With CKD on Hemodialysis
A Multicenter Single-arm Extension Study to Describe the Long-term Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis
Status: Enrolling
Updated:  7/11/2017
Clinical Research Facility
mi
from
Ocala, FL
To Assess the Long-term Safety of AMG 416 in the Treatment of SHPT in Subjects With CKD on Hemodialysis
A Multicenter Single-arm Extension Study to Describe the Long-term Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis
Status: Enrolling
Updated: 7/11/2017
Clinical Research Facility
mi
from
Ocala, FL
Click here to add this to my saved trials
To Assess the Long-term Safety of AMG 416 in the Treatment of SHPT in Subjects With CKD on Hemodialysis
A Multicenter Single-arm Extension Study to Describe the Long-term Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis
Status: Enrolling
Updated:  7/11/2017
Clinical Research Facility
mi
from
Pembroke Pines, FL
To Assess the Long-term Safety of AMG 416 in the Treatment of SHPT in Subjects With CKD on Hemodialysis
A Multicenter Single-arm Extension Study to Describe the Long-term Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis
Status: Enrolling
Updated: 7/11/2017
Clinical Research Facility
mi
from
Pembroke Pines, FL
Click here to add this to my saved trials
To Assess the Long-term Safety of AMG 416 in the Treatment of SHPT in Subjects With CKD on Hemodialysis
A Multicenter Single-arm Extension Study to Describe the Long-term Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis
Status: Enrolling
Updated:  7/11/2017
Clinical Research Facility
mi
from
Tampa, FL
To Assess the Long-term Safety of AMG 416 in the Treatment of SHPT in Subjects With CKD on Hemodialysis
A Multicenter Single-arm Extension Study to Describe the Long-term Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis
Status: Enrolling
Updated: 7/11/2017
Clinical Research Facility
mi
from
Tampa, FL
Click here to add this to my saved trials